Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein.

Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.

Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.

Abstract: This disclosure relates to methods for the treatment of neoplastic disorders by administering Compound 1, or a pharmaceutically acceptably salt thereof, on its own and/or as part of a conjugate or composition, and inducing production of at least one neoantigen.

Abstract: This disclosure relates to methods for the treatment of neoplastic disorders by administering Compound 1, or a pharmaceutically acceptably salt thereof, on its own and/or as part of a conjugate or composition, and inducing production of at least one neoantigen.

Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.

Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.

Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.

Abstract: A method and system for incrementally revising designated portions of content contained in a medium to provide a new edition and/or a revised edition of the medium, the method including assigning a unique identifier to each element of the content contained in the source version; creating for each element of the content, at least one of a change set file, a logical content store file, or a definition file; receiving from a first author a first modification to a discrete portion of the content, the first modification further comprising: a logical intent of the first author for the first modification, a purpose of the first author for the first modification, or a goal of the first author for the first modification; storing the first modification in a corresponding first change set file; receiving from a second author a second modification to the discrete portion of the content, the second modification further comprising: a logical intent of the second author for the second modification, a purpose of the second a

Abstract: This disclosure relates to methods for the treatment of neoplastic disorders by administering Compound 1, or a pharmaceutically acceptably salt thereof, on its own and/or as part of a conjugate or composition, and inducing production of at least one neoantigen.

Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.

Abstract: A system and method for processing leaded glass are presented, in which glass input is tumbled within the cylinder of a ball mill while it is being exposed to an electrolytic fluid. As the glass input is tumbled, balls within the ball mill pulverize the glass input into pulverized glass input particulate matter thereby exposing lead or other heavy metals contained within the glass input to a surface of the pulverized glass input particulate matter. The exposed lead or other heavy metals are largely dissolved by the electrolytic fluid leaving a mostly lead or heavy metal free pulverized glass input particulate matter. A reagent is applied to the pulverized glass input particulate matter to neutralize any residual lead or heavy metal within the pulverized glass input particulate matter thereby allowing the processed pulverized glass input particulate matter to pass a Toxicity Characteristic Leaching Procedure (TCLP) environmental test.

Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.

Abstract: A method and system for incrementally revising designated portions of content contained in a medium to provide a new edition and/or a revised edition of the medium, the method including assigning a unique identifier to each element of the content contained in the source version; creating for each element of the content, at least one of a change set file, a logical content store file, or a definition file; receiving from a first author a first modification to a discrete portion of the content, the first modification further comprising: a logical intent of the first author for the first modification, a purpose of the first author for the first modification, or a goal of the first author for the first modification; storing the first modification in a corresponding first change set file; receiving from a second author a second modification to the discrete portion of the content, the second modification further comprising: a logical intent of the second author for the second modification, a purpose of the second a

Abstract: An apparatus for conveying one or more objects along a conveying path in a conveying direction includes an endless conveyor chain formed of modular links arranged in rows in a direction transverse to the conveying direction. The links include spaced outer side links forming a part of a conveying surface for the objects to be conveyed and intermediate links interconnected with side links by connector rods, the chain having at least a forward run for conveying one or more objects in the conveying direction. A driver is provided for driving the conveyor chain, and includes a first sprocket adapted for engaging at least one side link along at least one side of the chain, the first sprocket mounted for rotation about an axis generally orthogonal to the conveying direction and the transverse direction. The sprocket may comprise a split sprocket, and may be adapted for pivoting movement.

Abstract: An apparatus for conveying one or more objects along a conveying path in a conveying direction includes an endless conveyor chain formed of modular links arranged in rows in a direction transverse to the conveying direction. The links include spaced outer side links forming a part of a conveying surface for the objects to be conveyed and intermediate links interconnected with side links by connector rods, the chain having at least a forward run for conveying one or more objects in the conveying direction. A driver is provided for driving the conveyor chain, and includes a first sprocket adapted for engaging at least one side link along at least one side of the chain, the first sprocket mounted for rotation about an axis generally orthogonal to the conveying direction and the transverse direction. The sprocket may comprise a split sprocket, and may be adapted for pivoting movement.

Abstract: The invention includes genetically modified dendritic cells expressing at least two immunosuppressive molecules. The genetically modified dendritic cells have the ability to induce tolerance. Enhanced tolerogenicity is useful for prolonging survival of a foreign transplant and for treatment of autoimmune diseases.